<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783909</url>
  </required_header>
  <id_info>
    <org_study_id>KE-0254/241/2014</org_study_id>
    <nct_id>NCT04783909</nct_id>
  </id_info>
  <brief_title>Refractive Outcomes After Cataract Surgery in Eyes With Pseudoexfoliation Syndrome</brief_title>
  <official_title>Refractive Outcomes of Phacoemulsification Cataract Surgery in Eyes With Pseudoexfoliation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the refractive outcomes of cataract surgery in PEX syndrome and determine which&#xD;
      of the commonly used IOL formulas (SRK/T, Barrett Universal II and Hill-RBF) is the best in&#xD;
      predicting postoperative refractive outcomes in PEX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome measure was to compare refractive outcomes (MAE, MedAE, percentage of&#xD;
      eyes within certain range of prediction error) in PEX and control eyes. The secondary outcome&#xD;
      measure was to determine whether any of IOL power prediction formulas (SRK/T, Barrett&#xD;
      Universal II and Hill-RBF) is more precise for these challenging eyes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To compare refractive outcomes in PEX and control eyes.</measure>
    <time_frame>3 months</time_frame>
    <description>To measure MAE, MedAE, percentage of eyes within certain range of prediction error after cataract surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether any of IOL power prediction formulas is more precise for these challenging eyes.</measure>
    <time_frame>3 months</time_frame>
    <description>To measure the effects of IOL power calculation formulas - SRK/T, Barrett Universal II and Hill-RBF - on postoperative refraction</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Refractive Errors</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>PEX</arm_group_label>
    <description>42 eyes with PEX syndrome and coexisting cataract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>38 eyes with cataract only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification cataract surgery</intervention_name>
    <description>All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PEX</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients above 18 yo with senile cataract with/without PEX without coexisting ocular&#xD;
        pathologies&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  senile cataract with/without PEX&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  corneal pathology&#xD;
&#xD;
          -  glaucoma,&#xD;
&#xD;
          -  corneal astigmatism greater than 2.0 diopters (D),&#xD;
&#xD;
          -  previous eye surgery or subjects with decreased vision due to other reasons than&#xD;
             cataract (e.g., exudative age-related macular degeneration (AMD), proliferative&#xD;
             diabetic retinopathy, inflammatory eye diseases),&#xD;
&#xD;
          -  intraoperative complications,&#xD;
&#xD;
          -  postoperative corrected distance visual acuity (CDVA) worse than 20/40,&#xD;
&#xD;
          -  axial length below 21 mm and above 25 mm,&#xD;
&#xD;
          -  dense cataracts or poor fixation requiring ultrasound biometry&#xD;
&#xD;
          -  eyes with manifest iridophacodonesis and those in which a capsular tension ring was&#xD;
             inserted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Å»arnowski, MD, PhD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University in Lublin</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pseudoexfoliation</keyword>
  <keyword>phacoemulsification cataract surgery</keyword>
  <keyword>IOL power calculation formulas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

